Tracers / [225Ac]Ac-DOTA-2Rs15d
[225Ac]Ac-DOTA-2Rs15d
Also written as [Ac-225]Ac-DOTA-2Rs15d
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- sdAb-DOTA (anti-HER2 single-domain antibody conjugated with DOTA chelator)
- Target / mechanism
- HER2 (human epidermal growth factor receptor type 2) PMID 36129807
- Clinical application
- Radioimmunotherapy of HER2-positive cancer using an alpha-particle-emitting single-domain antibody PMID 36129807
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | >90% | >98% | sdAb-DOTA (p-SCN-Bn-DOTA conjugated 2Rs15d) | 36129807 2022 Mol Cancer Ther The mixture was cooled to room temperature, quenched with 50 mmol/L DTPA and Chelex 100 — The radiolabeling yield was >90% (n = 21) for all bioconjugates labeled with 225Ac |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTA-2Rs15d, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36129807: 'sdAb-DOTA (p-SCN-Bn-DOTA conjugated 2Rs15d)'. Stage set/updated at stage 23 from PMID 36129807: 'Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.'.